SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?


To: Tomato who wrote (1173)11/5/2003 2:30:54 AM
From: stockselect1  Read Replies (1) | Respond to of 1833
 
Do not over think this. I would not wish to see a rts offering below $2.00. However, most rights offering are set at a discount to the current market price. That would be umacceptable. If more $ is put in at $2, then things will be great.



To: Tomato who wrote (1173)12/12/2003 2:02:17 PM
From: Tomato  Read Replies (2) | Respond to of 1833
 
Three year high, I do believe. Not a lot of volume, but maybe BMY is out of stock? Can't remember the last time there was a 10 cent move.

Maybe we'll get an announcement from Ms. Paige that she's made an acquisition?:

Dec. 25, 2003 (Reuters) Michelle Paige, CEO of Cadus Corporation (KDUS) announced today that the company has come to terms with Richard Harmon of Richard Harmon, Inc. to buy the Harmon Corporation for $1 and 15% of all annual profits Mr. Harmon produces as portfolio manager of the soon to be launched Cadus-Harmon Biotechnology Fund. The Fund will be a closed-end fund to be listed on the AMEX and will be funded with Cadus' approximate $25 million in cash as well as a $100 million infusion from controlling shareholder Carl Icahn.

Mr. Icahn, who was present at the news conference commented, "I can't think of a more productive place to put Cadus's and my monies. Mr. Harmon is an extraordinary biotech picker and will also be working to see that Cadus's patents and licenses bear fruit. It's a match made in heaven."